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1. INTRODUCTION {#cam42893-sec-0005}
===============

Breast cancer (BC) is the second most malignant tumor in the world, ranked after lung cancer. BC remains the leading cause of cancer deaths in Chinese women, placing a huge burden on public health.[1](#cam42893-bib-0001){ref-type="ref"} In China, new BC cases accounted for 12.2% of all new cancer cases and 9.6% of all deaths.[2](#cam42893-bib-0002){ref-type="ref"} With the Chinese population increasing and accelerated aging, the number of new BC cases has been continually rising in recent years and the age of onset tended to be younger.[3](#cam42893-bib-0003){ref-type="ref"} The high incidence and mortality of BC in China have become a public problem that seriously threatened women\'s physical and mental health.[4](#cam42893-bib-0004){ref-type="ref"} Finding the specific susceptibility biomarker and identifying individuals with higher risk of BC could be helpful to improve the early diagnostic rate of BC.

With the development of high‐throughput technology, emerging evidence demonstrated that genetic alterations, including single‐nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations, were associated with the risk of various diseases including BC.[5](#cam42893-bib-0005){ref-type="ref"}, [6](#cam42893-bib-0006){ref-type="ref"} Notably, SNPs, especially in irregular regions of protein‐coding and related with diseases, have been extensively studied and reported widely.[7](#cam42893-bib-0007){ref-type="ref"} The expression of the same lncRNA transcripts varies by different health conditions, age, tissues, even cells, which can indicate their potential as possible biomarkers and be predictive of diagnosis and prognosis of diseases.[8](#cam42893-bib-0008){ref-type="ref"}, [9](#cam42893-bib-0009){ref-type="ref"} Enormous studies have proven that lncRNAs were associated with tumorgenesis, progression, metastasis, and drug resistance, functioning as oncogenes, tumor suppressor genes, or both, involving in shaping multiple biological characteristics of cancer at transcriptional, posttranscriptional, and epigenetic levels.[10](#cam42893-bib-0010){ref-type="ref"}, [11](#cam42893-bib-0011){ref-type="ref"}, [12](#cam42893-bib-0012){ref-type="ref"} In addition, the abnormal expression levels of different lncRNAs with oncogenic and tumor suppressor functions have been frequently found in the development of BC.[13](#cam42893-bib-0013){ref-type="ref"} Particularly, adverse rules of miRNAs‐sponging lncRNAs, involved in ceRNA networks (ceRNETs), have been shown in BC.[14](#cam42893-bib-0014){ref-type="ref"} Eades discovered lincRNA‐ROR/miR‐145/ARF6 mRNA networks interacting with metastasis and prognosis in triple‐negative BC in 2015.[15](#cam42893-bib-0015){ref-type="ref"}

Long intergenic nonprotein coding RNA 520 (*LINC00520*) is located at human chromosome 14q22.3. *LINC00520*, a highly conserved long‐chain noncoding RNA with a length of about 20kb, is widely expressed in various tissues. A study reported that *LINC00520* was overexpressed in laryngeal squamous cell carcinoma tissue.[16](#cam42893-bib-0016){ref-type="ref"} The upregulation of *LINC00520* expression might play an important biological role in the metastasis of laryngeal squamous cell carcinoma. The expression of *LINC00520* was upregulated in primary nasopharyngeal carcinoma.[17](#cam42893-bib-0017){ref-type="ref"} In addition, the level of *LINC00520* was significantly increased in renal cell carcinoma.[18](#cam42893-bib-0018){ref-type="ref"} *LINC00520* promoted the migration of BC cells induced by *Src*, *STAT3*, and *PI3K* and played a functional role in BC.[19](#cam42893-bib-0019){ref-type="ref"} Although it was reported that the lncRNA *LINC00520* was associated with BC, the complexity of its function was also determined by the complexity of the lncRNAs structure. However, the association among *LINC00520* SNPs and the susceptibility of BC and its mechanism is not clear yet. In this study, the combined database, literature retrieval, and bioinformatics techniques were used to screen lncRNA and its SNP site associated with BC. The association between long noncoding RNA genetic variation and BC susceptibility was studied, as well as biological function was explored by the method of molecular epidemiology.

2. MATERIALS AND METHODS {#cam42893-sec-0006}
========================

2.1. Study subjects {#cam42893-sec-0007}
-------------------

A total of 1009 subjects were enrolled in the study, including 504 cases with BC and 505 age‐matched (±2 years) healthy controls (Table [1](#cam42893-tbl-0001){ref-type="table"}). Subjects were included in accordance with strict standards: (a) Patients with BC must have a definite pathological diagnosis of new cases; (b) The patients with BC were selected from the First Affiliated Hospital and the Third Affiliated Hospital of Zhengzhou University from 2013 to 2015; (c) Patients with BC have never received radiotherapy or chemotherapy or any other treatment before; (d) Except BC, there were no other diseases in all cases.

###### 

Basic characteristics of 504 breast cancer cases and 505 healthy controls

  Variables                     Cases (%)      Controls (%)   *P* [a](#cam42893-note-0004){ref-type="fn"}      OR (95%CI)
  ----------------------------- -------------- -------------- ------------------------------------------------ -----------------------
  Age (mean ± SD)               48.00 ± 9.85   48.15 ± 9.61   .906[b](#cam42893-note-0005){ref-type="fn"}       
  Age at menarche (mean ± SD)   14.21 ± 1.70   13.97 ± 1.75   *.030* [b](#cam42893-note-0005){ref-type="fn"}    
  Menopause state                                                                                              
  Premenopause                  320 (63.5)     294 (58.2)                                                      1.000
  Postmenopause                 184 (36.5)     211 (41.8)     .086                                             0.801 (0.622‐1.032)
  Age at menopause                                                                                             
  ≤50                           129 (70.1)     146 (69.2)                                                      1.000
  \>50                          55 (29.9)      65 (30.8)      .844                                             0.958 (0.623‐1.472)
  Number of pregnancies                                                                                        
  ≤1                            53 (10.5)      94 (18.6)                                                       1.000
  2                             129 (25.6)     177 (35.0)     .215                                             1.293 (0.861‐1.940)
  3                             135 (26.8)     128 (25.3)     .262                                             1.898 (0.620‐5.816)
  ≥4                            187 (37.1)     106 (21.0)     *.043*                                           *3.175 (1.037‐9.722)*
  Number of abortion                                                                                           
  ≤1                            340 (67.5)     345 (68.3)                                                      1.000
  2                             105 (20.8)     117 (23.2)     .545                                             0.911 (0.673‐1.233)
  3                             35 (6.9)       30 (5.9)       .735                                             0.913 (0.537‐1.551)
  ≥4                            24 (4.8)       13 (2.6)       .308                                             1.444 (0.713‐2.926)
  Breastfeeding                                                                                                
  No                            121 (24.0)     94 (18.6)                                                       1.000
  Yes                           383 (76.0)     411 (81.4)     *.037*                                           *0.724 (0.535‐0.980)*
  Family history                                                                                               
  No                            461 (91.5)     481 (95.2)                                                      1.000
  Yes                           43 (8.5)       24 (4.8)       *.017*                                           *1.869 (1.116‐3.130)*
  ER                                                                                                           
  Negative                      149 (30.3)                                                                      
  Positive                      342 (69.7)                                                                      
  PR                                                                                                           
  Negative                      191 (39.1)                                                                      
  Positive                      298 (60.9)                                                                      
  HER‐2                                                                                                        
  Negative                      136 (29.3)                                                                      
  Positive                      328 (70.7)                                                                      

Abbreviations: ER, estrogen receptor; HER‐2, human epidermal growth factor receptor‐2; PR, progesterone receptor.

Two‐sided Chi‐square test, *P* \< .05 was statistically different.

Student\'s *t* test.

The italic values represent *P* \< .05.
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The control was collected from the site of an epidemiological survey of cardiovascular disease involving more than 20 000 people in Henan Province during the same time. The healthy controls were matched with the BC group according to the age (±2 years), who were healthy without any history of cancer or any other chronic disease. None of the participants had any affinity.

All subjects volunteered to participate in the study and signed informed consent. The study has been approved by the Medical and Health Research Ethics Committee of Zhengzhou University.

2.2. Data collection {#cam42893-sec-0008}
--------------------

The data of the patients with BC were obtained through medical records of the hospital, including names, ages, nationality, place of origin, menarche age, menopause status, whether there was a history of breastfeeding and childbearing, cancer history of first‐degree relatives (parents, siblings, and children), second‐degree relatives (grandparents, uncles, aunts), along with estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor‐2 (Her‐2).

The data of controls were collected by face‐to‐face questionnaire designed by experts, asked by trained investigators. The content of the data was the same as BC cases. All the collected information was entered parallel with EpiData software. The whole process of investigation was carried out under strict quality control, including collection, collation, and entry of information.

2.3. DNA extraction {#cam42893-sec-0009}
-------------------

Peripheral blood (5 mL) was collected from each subject using an anticoagulation vessel containing ethylenediaminetetraacetic acid (EDTA) for DNA extraction and genotyping. The genomic DNA was extracted using genomic DNA extraction kit (DK601‐02 centrifugal column type) of Shanghai Lifefeng Biotech Co., Ltd and the operation process was carried out in accordance with the instructions strictly. All the extracted genomic DNA was labeled, measured, and finally stored in −80°C refrigerator for future use.

2.4. SNPs selection and genotyping {#cam42893-sec-0010}
----------------------------------

LncRNA database (<http://www.lncrnadb.org/>), NCBI database (<https://www.ncbi.nlm.nih.gov/gene/>), Ensembl database (<http://asia.ensembl.org/Homo_sapiens/Info/Index>), and 1000 Genomes Browser (<http://browser.1000genomes.org/index.html>) were used to determine the location of *LINC00520*. We selected the tagger SNPs in region of *LINC00520* by lncRNASNP2 database (<http://bioinfo.life.hust.edu.cn/lncRNASNP>) based on Chinese Han population data of HapMap Project (HapMap Rel28, NCBI B36) with the criteria of a minor allele frequency (MAF) higher than 0.1 in Chinese Han population and the pairwise correlation was set as *r* ^2^ less than .8, which can reflect the degree of chain reaction between SNP. Secondly, we screened the SNP located in the Promoter Flanking Region and Enhancer regions of *LINC00520*. Then, lncRNASNP2 (<http://bioinfo.life.hust.edu.cn/lncRNASNP>) database was used to predict the potential miRNA binding sites of the selected SNPs. RNAfold website (<http://rna.tbi.univie.ac.at/cgibin/RNAWebSuite/RNAfold.cgi>) was utilized to predict the influence of the selected SNPs in *LINC00520* on the secondary structure of *LINC00520* (Table [S1](#cam42893-sup-0004){ref-type="supplementary-material"}). Finally, nine SNPs (rs11622641, rs7157819, rs12880540, rs2152275, rs4144657, rs2152278, rs7142488, rs8008130, and rs8012083) in *LINC00520* were selected for further research (Table [S2](#cam42893-sup-0005){ref-type="supplementary-material"}).

In this study, rs11622641, rs7157819, rs12880540, and rs2152275 located in *LINC00520* were genotyped by SNPscan. Because of the low score of other SNPs, SNPscan method was not suitable. Polymerase chain reaction‐restriction fragment length polymorphism (PCR‐RFLP) technique was used for genotyping of rs4144657, rs2152278, and rs7142488 in *LINC00520*, while rs8008130 and rs8012083 using created restriction site PCR (CRS‐RFLP). While there was no suitable restriction endonuclease near the mutation site, we needed to change a base on the primer so that a new restriction site could be formed with the base of the mutation site, thus CRS‐RFLP method was used. Primers for PCR amplification were designed using primer 6.0 software. NCBI BLAST website (<https://www.ncbi.nlm.nih.gov/tools/primer-blast/>) was used to evaluate the specificity of primers. Gradient PCR technique was used to standardize the conditions of DNA amplification and optimize the annealing temperature for the primers set. The suitable restriction enzymes were selected by WatCut website (<http://watcut.uwaterloo.ca/template.php>; Table [S3](#cam42893-sup-0006){ref-type="supplementary-material"}). Moreover, approximately 5% of samples were randomly selected for Sanger sequencing, yielding a 100% concordance rate between the two methods.

2.5. Quantitative real‐time PCR analysis {#cam42893-sec-0011}
----------------------------------------

The relative expression of *LINC00520* was detected by the Eco Real‐Time PCR System (Illumina). The primers of *LINC00520* and *GAPDH* were synthesized by TaKaRa Biotechnology Co. Ltd. The reaction conditions of qRT‐PCR were performed in strict accordance with the following instructions. All specific primers used in quantitative RT‐PCR were shown below, *LINC00520* primer: 5′‐AAGCAGGACACAATTACAAC‐3′ and 5′‐GCAGGTCCGAGGTATTCGTC‐3′, *GAPDH* primer: 5′‐CGGAGTCAACGGATTTGGTCGTAT‐3′ and 5′‐AGCCTTCTTCATGGTGGTGAAGAC‐3′. All samples were independently measured in triplicate. Finally, the relative expression of the gene was the average of three replicates per sample. The relative expression of *LINC00520* was calculated by 2^−ΔΔCT^ method, and *GAPDH* was used as the internal reference gene (X ± SD).[20](#cam42893-bib-0020){ref-type="ref"}

2.6. Cell culture, transfection, and luciferase reporter assay {#cam42893-sec-0012}
--------------------------------------------------------------

To further examine whether rs12880540 could have impact on the binding of miR‐3122 and *LINC00520*, predicted by lncRNASNP2 database (Figure [S1](#cam42893-sup-0001){ref-type="supplementary-material"}), 293T cell lines were obtained and grown in DMEM supplemented with 10% fetal bovine serum (GIBCO) in a humidified atmosphere of 5% CO2 at 37°C. All cell lines were never subcultured for more than 3 months and sequenced by DNA using the Applied Biosystems Amp F/STR Identifier kit and last performed in September 2018. The miR‐3122 mimics and negative control (NC) were synthesized in Genecreate. For transfection assays, 293T cells were seeded in 48‐well plates and simultaneously transfected with PGL3‐basic‐luc vector and miR‐3122 or NC mimics using Lipofectamine 3000 (Invitrogen). After 48 hours, cells were harvested, and Renilla luciferase/Firefly luciferase activities between different alleles were detected and analyzed according to the manufacturer\'s instruction (dual luciferase assay system, Promega). All experiments were performed independently in triplicate.

2.7. Quality control {#cam42893-sec-0013}
--------------------

Negative control was performed for each batch of PCR amplification to avoid false positive of sample contamination. About 5% of samples were randomly selected for sequencing to ensure the reliability of genotyping results. Figure [S2](#cam42893-sup-0002){ref-type="supplementary-material"} showed the PCR‐RFLP and CRS‐RFLP techniques, while the sequencing results were shown in Figure [S3](#cam42893-sup-0003){ref-type="supplementary-material"}. The qRT‐PCR experiments were repeated three times independently to reduce the measurement error.

2.8. Statistical analysis {#cam42893-sec-0014}
-------------------------

The sample size of the study (n = 460) was calculated using Power Analysis and Sample Size (PASS) software based on study power (0.9) and minimal alleles frequency (0.1). *Student\'s* *t* test was used for continuous normal distribution variables and Chi‐square test was used to classify variables. Hardy‐Weinberg equilibrium (HWE) was examined to compare the observed genotype frequencies of cancer‐free controls with the expected genotype frequencies by goodness‐of‐fit Chi‐square test. Odds ratios (ORs) and its 95% confidence intervals (CIs) were calculated to evaluate the association between SNPs and BC susceptibility adjusted for potential confounding factors, including age, age of menarche, age of menopause, menopausal status, pregnancy number, abortion number, breastfeeding history, and family history of BC in first‐degree relatives. MDR 2.0 software was used to analyze interaction between polymorphic sites in lncRNA gene and reproductive factors. SHEsis (<http://analysis.bio-x.cn/myAnalysis.php>) was conducted to calculate the difference of haplotype frequencies in both patients and controls. The input of data was carried out by EpiData software with double parallel entry. The statistical analysis was performed by SPSS 23.0 software.

3. RESULTS {#cam42893-sec-0015}
==========

3.1. Characteristics of the participants {#cam42893-sec-0016}
----------------------------------------

The average age of BC cases was 48.00 years (±9.85), while that of the control group was 48.15 years (±9.61). No statistical differences were found in the distribution of age, menopause state, age at menopause, and number of abortion between the BC cases and cancer‐free controls (all *P* \> .05). The mean age at menarche was 14.21 years (±1.70) in BC patients and 13.97 years (±1.75) in controls (*P* = .03). Breastfeeding was a protective factor (OR:0.73, 95%CI:0.54‐0.98), while carrying family history of tumor was a risk factor for BC cases (OR:1.87, 95%CI:1.12‐3.13). Approximately, half of the patients were positive in ER, PR, and Her‐2 (342 \[69.7%\], 298 \[60.9%\], and 328 \[70.7%\], respectively).

3.2. The associations between SNP genotypes and risk of BC {#cam42893-sec-0017}
----------------------------------------------------------

As indicated in Table [2](#cam42893-tbl-0002){ref-type="table"}, the genotype distributions of the nine SNPs in control group all conformed to HWE (*P* \> .05). The relationship between SNPs and BC risk based on different genetic models is summarized in Table [2](#cam42893-tbl-0002){ref-type="table"}. When after adjusting the confounding factors in logistic regression analysis, the unconditional multiple logistic regression based on the dominant (OR:0.65, 95%CI:0.45‐0.95) and overdominant genetic model (OR:0.67, 95%CI:0.46‐0.98) consistently showed that rs11622641 T was significantly associated with lower risk of BC. Similarly, the recessive genetic model (OR:1.57, 95%CI:1.07‐2.30) also showed that the individuals with 12880540 G had increased risk of BC. The dominant (OR:1.62, 95%CI:1.24‐2.11) and overdominant (OR:1.56, 95%CI:1.19‐2.03) genetic model also revealed that rs2152278 T could increase the risk of BC.

###### 

Association between nine SNPs of *LINC00520* and breast cancer susceptibility

  SNPs genetic model   Genotype       Cases (%)    Controls (%)   *P* [a](#cam42893-note-0006){ref-type="fn"}   *P* [b](#cam42893-note-0007){ref-type="fn"}   OR (95%CI)              *P* [c](#cam42893-note-0008){ref-type="fn"}
  -------------------- -------------- ------------ -------------- --------------------------------------------- --------------------------------------------- ----------------------- ---------------------------------------------
  rs11622641                                                      *.030*                                        .995                                                                   
  Codominant           CC             445 (88.3)   417 (82.6)     Reference                                                                                   1.000                    
  CT                   57 (11.3)      84 (16.6)    *.014*                                                       *0.666 (0.453‐0.979)*                         *.039*                  
  TT                   2 (0.4)        4 (0.8)      .439                                                         0.359 (0.056‐2.289)                           .278                    
  Dominant             CT + TT/CC                                                                                                                             *0.650 (0.445‐0.949)*   *.026*
  Recessive            TT/CC + CT                                                                                                                             0.375 (0.059‐2.393)     .299
  Overdominant         CT/CC + TT                                                                                                                             *0.670 (0.455‐0.984)*   *.041*
  rs7157819                                                       .556                                          .821                                                                   
  Codominant           CC             375 (74.4)   391 (77.4)     Reference                                                                                   1.000                    
  CT                   119 (23.6)     105 (20.8)   .288                                                         1.054 (0.768‐1.445)                           .746                    
  TT                   10 (2.0)       9 (1.8)      .819                                                         0.971 (0.372‐1.445)                           .952                    
  Dominant             CT + TT/CC                                                                                                                             1.047 (0.770‐1.423)     .770
  Recessive            TT/CC + CT                                                                                                                             0.959 (0.369‐2.492)     .931
  Overdominant         CT/CC + TT                                                                                                                             1.054 (0.769‐1.445)     .742
  rs12880540                                                      .069                                          .460                                                                   
  Codominant           TT             208 (41.3)   218 (43.2)     Reference                                                                                   1.000                    
  TG                   222 (44.0)     237 (46.9)   .893                                                         1.025 (0.776‐1.354)                           .863                    
  GG                   74 (14.7)      50 (9.9)     *.041*                                                       *1.551 (1.034‐2.328)*                         *.034*                  
  Dominant             TG + GG/TT                                                                                                                             1.098 (0.843‐1.429)     .488
  Recessive            GG/ TG + TT                                                                                                                            *1.566 (1.069‐2.295)*   *.021*
  Overdominant         TG/GG + TT                                                                                                                             0.948 (0.730‐1.232)     .690
  rs2152275                                                       .886                                          .680                                                                   
  Codominant           TT             271 (53.8)   265 (52.5)     Reference                                                                                   1.000                    
  TA                   199 (39.5)     207 (41.0)   .646                                                         1.001 (0.763‐1.315)                           .992                    
  AA                   34 (6.7)       33 (6.5)     .997                                                         1.128 (0.658‐1.933)                           .661                    
  Dominant             TA + AA/TT                                                                                                                             1.018 (0.784‐1.322)     .892
  Recessive            AA/TA + TT                                                                                                                             1.127 (0.667‐1.906)     .655
  Overdominant         TA/AA + TT                                                                                                                             0.988 (0.758‐1.289)     .930
  rs8008130                                                       .702                                          .644                                                                   
  Codominant           CC             418 (82.9)   427 (84.6)     Reference                                                                                   1.000                    
  CA                   79 (15.7)      73 (14.5)    .598                                                         1.165 (0.810‐1.674)                           .411                    
  AA                   7 (1.4)        5 (1.0)      .575                                                         1.448 (0.410‐5.111)                           .565                    
  Dominant             CA + AA/CC                                                                                                                             1.182 (0.831‐1.681)     .352
  Recessive            AA/CA + CC                                                                                                                             1.418 (0.403‐4.997)     .586
  Overdominant         CA/AA + CC                                                                                                                             0.862 (0.600‐1.239)     .424
  rs4144657                                                       .252                                          .122                                                                   
  Codominant           CC             147 (29.2)   126 (25.0)     Reference                                                                                   1.000                    
  CT                   267 (53.0)     275 (54.5)   .235                                                         0.859 (0.632‐1.168)                           .333                    
  TT                   90 (17.9)      104 (20.6)   .133                                                         0.756 (0.511‐1.117)                           .160                    
  Dominant             CT + TT/CC                                                                                                                             1.204 (0.897‐1.615)     .216
  Recessive            TT/CC + CT                                                                                                                             0.836 (0.599‐1.167)     .292
  Overdominant         CT/CC + TT                                                                                                                             0.964 (0.742‐1.253)     .785
  rs2152278                                                       .001                                          .080                                                                   
  Codominant           GG             180 (35.7)   238 (47.1)     Reference                                                                                   1.000                    
  GT                   250 (49.6)     194 (38.4)   \<.001                                                       *1.700 (1.278‐2.261)*                         *\<.001*                
  TT                   74 (14.7)      73 (14.5)    .148                                                         1.398 (0.939‐2.080)                           .099                    
  Dominant             GT + TT/GG                                                                                                                             *1.619 (1.239‐2.114)*   \<*.001*
  Recessive            TT/GT + GG                                                                                                                             1.062 (0.735‐1.535)     .749
  Overdominant         GT/TT + GG                                                                                                                             *1.556 (1.194‐2.026)*   *.001*
  rs8012083                                                       .104                                          .522                                                                   
  Codominant           AA             288 (57.1)   311 (61.6)     Reference                                                                                   1.000                    
  AG                   185 (36.7)     176 (34.9)   .351                                                         1.127 (0.855‐1.485)                           .398                    
  GG                   31 (6.2)       18 (3.6)     .053                                                         1.666 (0.886‐3.133)                           .113                    
  Dominant             AG + GG/AA                                                                                                                             1.179 (0.904‐1.539)     .224
  Recessive            GG/AG + AA                                                                                                                             1.593 (0.855‐2.970)     .143
  Overdominant         AG + GG + AA                                                                                                                           1.085 (0.826‐1.424)     .559
  rs7142488                                                       .364                                          .981                                                                   
  Codominant           TT             410 (81.3)   415 (82.2)     Reference                                                                                   1.000                    
  TC                   93 (18.5)      86 (17.0)    .621                                                         1.157 (0.823‐1.626)                           .402                    
  CC                   1 (0.2)        4 (0.8)      .374                                                         0.241 (0.026‐2.209)                           .208                    
  Dominant             TC + CC/TT                                                                                                                             1.111 (0.794‐1.555)     .539
  Recessive            CC/TC + TT                                                                                                                             0.235 (0.026‐2.146)     .199
  Overdominant         TC/CC + TT                                                                                                                             1.166 (0.830‐1.639)     .375

*P* value of Chi‐square test for comparison of genotype frequency between case and control groups.

*P* value of Hardy‐Weinberg test in control population.

*P* values adjusted for age, menarche age, menopausal status, number of pregnancies, number of abortions, history of breastfeeding, and family history of breast cancer in first‐degree relatives in logistic regression analysis.

The italic values represent *P* \< .05.

John Wiley & Sons, Ltd

3.3. Stratified analysis of SNP genotypes and BC risk {#cam42893-sec-0018}
-----------------------------------------------------

We also examined the effect of SNPs on BC susceptibility in different subgroups of demographic factors (Table [3](#cam42893-tbl-0003){ref-type="table"}). CT + TT in rs11622641 was a protective genotype of BC susceptibility in females with age less than or equal to 50 years (OR:0.55, 95%CI:0.33‐0.92), age at menarche less than 14 years (OR:0.55, 95%CI:0.34‐0.88), number of pregnancy more than twice (OR:0.60, 95%CI:0.36‐0.98), and number of abortion less than twice (OR:0.64, 95%CI:0.43‐0.94). BC risk increased in individuals carrying rs7157819 CT + TT and having had two or more abortions (OR:4.19; 95%CI:1.14‐9.49). Subjects at greater risk, who had a younger menopause age (≤50 years), carried variant genotypes TG + GG of rs12880540 (OR:1.80, 95%CI:1.06‐3.07). For CT + TT of rs4144657, the risk of BC was decreased in population who had no menopause (OR:0.65, 95%CI:0.44‐0.95) or without a family history of BC (OR:0.23, 95%CI:0.06‐0.87). The genotype GT + GG of rs2152278 increased the risk of BC in population who was less than 50 years (OR:1.63, 95%CI:1.16‐2.29), age at menarche less than 14 years (OR:1.52, 95%CI:1.10‐2.11), no menopause (OR:1.67, 95%CI:1.18‐2.36).

###### 

Stratified analysis of nine SNPs in *LINC00520* and genetic susceptibility to breast cancer

                                    rs11622641 (CT + TT/CC)   rs7157819 (CT + TT/CC)   rs12880540 (TG + GG/TT)   rs2152275 (TA + AA/TT)                                                        
  --------------------------------- ------------------------- ------------------------ ------------------------- ------------------------ --------------------- -------- --------------------- ------
  Age (year)                                                                                                                                                                                   
  ≤50                               *0.549 (0.327‐0.923)*     *.024*                   1.084 (0.731‐1.606)       .689                     1.029 (0.738‐1.433)   .868     0.944 (0.678‐1.316)   .735
  \>50                              0.743 (0.419‐1.315)       .307                     1.155 (0.690‐1.934)       .583                     1.215 (0.770‐1.915)   .403     1.174 (0.754‐1.827)   .478
  Age at menarche (year)                                                                                                                                                                       
  ≤14                               *0.549 (0.342‐0.880)*     *.013*                   1.137 (0.778‐1.661)       .506                     1.173 (0.848‐1.622)   .334     0.891 (0.646‐1.229)   .482
  \>14                              0.976 (0.503‐1.892)       .943                     0.902 (0.525‐1.549)       .708                     1.024 (0.640‐1.639)   .920     1.488 (0.931‐2.380)   .097
  Age at menopause (year)                                                                                                                                                                      
  ≤50                               0.764 (0.378‐1.541)       .452                     1.149 (0.640‐2.063)       .642                     1.800 (1.055‐3.070)   *.031*   1.148 (0.693‐1.900)   .592
  \>50                              0.461 (0.171‐1.248)       .127                     0.892 (0.352‐2.258)       .809                     1.104 (0.489‐2.492)   .811     1.501 (0.655‐3.439)   .337
  Menopause state                                                                                                                                                                              
  Premenopause                      0.604 (0.354‐1.032)       .065                     1.142 (0.757‐1.722)       .527                     0.932 (0.661‐1.313)   .686     0.902 (0.640‐1.272)   .557
  Postmenopause                     0.696 (0.401‐1.206)       .196                     1.023 (0.634‐1.650)       .927                     1.449 (0.941‐2.231)   .092     1.249 (0.823‐1.897)   .296
  Number of pregnancies                                                                                                                                                                        
  ≤2                                0.785 (0.441‐1.397)       .411                     0.941 (0.565‐1.568)       .816                     1.289 (0.855‐1.942)   .225     1.195 (0.786‐1.818)   .405
  \>2                               *0.596 (0.363‐0.980)*     *.041*                   1.130 (0.755‐1.691)       .551                     0.952 (0.670‐1.352)   .783     0.963 (0.677‐1.370)   .836
  Number of abortions                                                                                                                                                                          
  ≤2                                *0.637 (0.434‐0.935)*     *.021*                   0.925 (0.668‐1.282)       .641                     1.061 (0.808‐1.393)   .672     1.126 (0.851‐1.490)   .407
  \>2                               0.777 (0.173‐3.495)       .742                     *4.192 (1.135‐9.486)*     *.032*                   1.609 (0.672‐3.852)   .286     0.591 (0.250‐1.396)   .231
  Breastfeeding                                                                                                                                                                                
  No                                0.518 (0.211‐1.270)       .151                     1.321 (0.690‐2.527)       .401                     1.357 (0.742‐2.484)   .322     1.008 (0.564‐1.803)   .979
  Yes                               0.719 (0.469‐1.100)       .128                     1.022 (0.718‐1.456)       .902                     1.078 (0.797‐1.457)   .627     1.027 (0.764‐1.380)   .860
  Family history of breast cancer                                                                                                                                                              
  No                                0.705 (0.472‐1.052)       .087                     1.015 (0737‐1.398)        .927                     1.050 (0.796‐1.384)   .732     1.007 (0.767‐1.321)   .961
  Yes                               0.370 (0.095‐1.440)       .152                     1.016 (0.272‐3.793)       .981                     1.967 (0.673‐5.753)   .216     1.146 (0.388‐3.386)   .805

                                    rs8008130 (CA + AA/CC)   rs4144657 (CT + TT/CC)   rs2152278 (GT + TT/GG)   rs8012083 (AG + GG/AA)   rs7142488 (CT + TT/CC)                                                                  
  --------------------------------- ------------------------ ------------------------ ------------------------ ------------------------ ------------------------ ---------- --------------------- ------ ---------------------- ------
  Age (year)                                                                                                                                                                                                                    
  ≤50                               1.070 (0.680‐1.684)      .771                     0.709 (0.491‐1.024)      .067                     *1.630 (1.162‐2.285)*    *.005*     1.212 (0.866‐1.695)   .262   1.248 (0.826‐1.885)    .293
  \>50                              1.466 (0.823‐2.612)      .194                     1.284 (0.768‐2.145)      .341                     1.471 (0.935‐2.315)      .095       1.218 (0.776‐1.909)   .391   0.878 (0.479‐1.610)    .673
  Age at menarche (year)                                                                                                                                                                                                        
  ≤14                               1.462 (0.944‐2.264)      .089                     0.829 (0.581‐1.184)      .303                     *1.520 (1.096‐2.108)*    *.012*     1.260 (0.912‐1.741)   .161   1.104 (0.732‐1.665)    .637
  \>14                              0.872 (0.473‐1.605)      .660                     0.832 (0.483‐1.432)      .506                     *1.909 (1.185‐3.074)*    *.008*     1.001 (0.616‐1.627)   .997   0.904 (0.492‐1.659)    .744
  Age at menopause (year)                                                                                                                                                                                                       
  ≤50                               1.314 (0.690‐2.506)      .406                     1.156 (0.640‐2.090)      .631                     1.385 (0.820‐2.338)      .224       0.928 (0.555‐1.551)   .775   0.765 (0.374‐1.565)    .463
  \>50                              1.767 (0.571‐5.472)      .324                     2.382 (0.915‐6.201)      .076                     1.243 (0.550‐2.812)      .601       1.092 (0.493‐2.418)   .828   0.794 (0.264‐2.387)    .682
  Menopause state                                                                                                                                                                                                               
  Premenopause                      1.085 (0.677‐1.738)      .736                     *0.650 (0.444‐0.951)*    *.027*                   *1.669 (1.179‐2.363)*    *.004*     1.330 (0.938‐1.887)   .110   1.355 (0.888‐2.067)    .159
  Postmenopause                     1.424 (0.828‐2.448)      .201                     1.415 (0.866‐2.312)      .165                     1.452 (0.943‐2.234)      .090       0.988 (0.647‐1.507)   .954   0.773 (0.432‐1.382)    .385
  Number of pregnancies                                                                                                                                                                                                         
  ≤2                                0.867 (0.487‐1.545)      .629                     1.028 (0.654‐1.614)      .906                     *1.707 (1.129‐2.581)*    *.011*     1.332 (0.886‐2.002)   .168   1.131 (0.689‐1.856)    .625
  \>2                               1.494 (0.940‐2.375)      .090                     0.745 (0.503‐1.104)      .142                     *1.608 (1.130‐2.288)*    *.008*     1.107 (0.780‐1.572)   .569   1.126 (0.707‐1.796)    .617
  Number of abortions                                                                                                                                                                                                           
  ≤2                                1.105 (0.766‐1.594)      .592                     0.850 (0.626‐1.154)      .296                     *1.579 (1.198‐2.080)*    *.001*     1.243 (0.945‐1.636)   .120   1.098 (0.772‐1.562)    .603
  \>2                               1.616 (0.509‐5.135)      .415                     0.617 (0.243‐1.571)      .311                     *3.249 (1.289‐8.188)*    *.012*     0.958 (0.397‐2.315)   .924   1.055 (0.368‐3.022)    .921
  Breastfeeding                                                                                                                                                                                                                 
  No                                0.598 (0.262‐1.367)      .223                     0.674 (0.354‐1.285)      .229                     *2.180 (1.178‐4.035)*    *.013*     1.344 (0.744‐2.426)   .327   1.052 (0.492‐2.251)    .896
  Yes                               1.421 (0.957‐2.108)      .084                     0.891 (0.638‐1.245)      .500                     *1.503 (1.115‐2.027)*    *.008*     1.150 (0.852‐1.554)   .360   1.090 (0.747‐1.590)    .656
  Family history of breast cancer                                                                                                                                                                                               
  No                                1.161 (0.806‐1.672)      .422                     0.896 (0.659‐1.218)      .483                     *1.643 (1.244‐2.170)*    \<*.001*   1.135 (0.861‐1.498)   .369   1.080 (0.763‐1.528)    .665
  Yes                               2.196 (0.400‐12.052)     .365                     *0.230 (0.061‐0.871)*    *.030*                   1.158 (0.399‐3.363)      .788       3.074 (0.967‐9.771)   .057   2.835 (0.487‐16.498)   .246

*P* values adjusted for age, menarche age, menopausal status, number of pregnancies, number of abortions, history of breastfeeding, and family history of breast cancer in first‐degree relatives in logistic regression analysis.

The italic values represent *P* \< .05.
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3.4. Receptor status and the genotypes of nine SNPs {#cam42893-sec-0019}
---------------------------------------------------

As shown in Table [4](#cam42893-tbl-0004){ref-type="table"}, only the genotype TG (OR:1.62, 95%CI:1.04‐2.52) in rs12880540, the genotype AA (OR:2.74, 95%CI:1.01‐7.42) in rs2152275, and GG (OR:0.31, 95%CI:0.14‐0.69) in rs8012083 were associated with HER‐2 status. There was no discovery between SNPs and ER and PR.

###### 

Association analysis between three SNPs in *LINC00520* and ER, PR, and Her‐2 receptor status in breast cancer patients

  SNPs Genotype   ER    *P* [a](#cam42893-note-0010){ref-type="fn"}   OR (95%CI)[a](#cam42893-note-0010){ref-type="fn"}   PR                    *P* [a](#cam42893-note-0010){ref-type="fn"}   OR (95%CI)[a](#cam42893-note-0010){ref-type="fn"}   Her‐2   *P* [a](#cam42893-note-0010){ref-type="fn"}   OR (95%CI)[a](#cam42893-note-0010){ref-type="fn"}                  
  --------------- ----- --------------------------------------------- --------------------------------------------------- --------------------- --------------------------------------------- --------------------------------------------------- ------- --------------------------------------------- --------------------------------------------------- ----- -------- -----------------------
  rs11622641                                                                                                                                                                                                                                                                                                                                                               
  CC              135   299                                                                                               1                     171                                           260                                                         1.000                                         120                                                 295            1
  CT              16    40                                            .912                                                1.036 (0.553‐1.939)   21                                            35                                                  .789    1.083 (0.603‐1.948)                           18                                                  36    .572     0.832 (0.439‐1.576)
  TT              0     2                                             1.000                                               0                     0                                             2                                                   1.000   NC                                            0                                                   2     1.000    0
  CT + TT         16    42                                            .741                                                1.110 (0.597‐2.067)   21                                            37                                                  .619    1.159 (0.649‐2.069)                           18                                                  38    .724     0.892 (0.475‐1.678)
  rs7157819                                                                                                                                                                                                                                                                                                                                                                
  CC              116   252                                                                                               1                     141                                           225                                                         1                                             108                                                 249            1
  CT              32    82                                            .604                                                1.133 (0.706‐1.819)   48                                            65                                                  .344    0.809 (0.521‐1.255)                           26                                                  81    .333     1.285 (0.773‐2.134)
  TT              2     7                                             .987                                                0.988 (0.248‐3.943)   3                                             7                                                   .557    0.515 (0.379‐6.052)                           4                                                   3     .099     0.273 (0.059‐1.275)
  CT + TT         35    89                                            .626                                                1.121 (0.709‐1.772)   51                                            72                                                  .454    0.849 (0.554‐1.301)                           30                                                  84    .578     1.148 (0.706‐4.866)
  rs12880540                                                                                                                                                                                                                                                                                                                                                               
  TT              63    140                                                                                               1                     78                                            123                                                         1                                             68                                                  132            1
  TG              65    151                                           .679                                                1.094 (0.715‐1.673)   81                                            134                                                 .674    1.090 (0.729‐1.632)                           52                                                  154   *.034*   *1.617 (1.037‐2.522)*
  GG              23    50                                            .689                                                0.887 (0.492‐1.598)   32                                            40                                                  .324    0.756 (0.434‐1.318)                           18                                                  47    .556     1.210 (0.641‐2.283)
  TG + GG         88    201                                           .855                                                1.038 (0.698‐1.542)   114                                           174                                                 .972    0.993 (0.682‐1.447)                           70                                                  201   .051     1.508 (0.998‐2.278)
  rs2152275                                                                                                                                                                                                                                                                                                                                                                
  TT              77    186                                                                                               1                     103                                           158                                                         1                                             79                                                  172            1
  TA              66    129                                           .267                                                0.795 (0.530‐1.192)   75                                            119                                                 .869    1.033 (0.701‐0.524)                           54                                                  132   .535     1.143 (0.749‐1.743)
  AA              8     26                                            .583                                                1.267 (0.544‐2.956)   14                                            20                                                  .805    0.911 (0.435‐1.908)                           5                                                   29    *.048*   *2.735 (1.008‐7.418)*
  TA + AA         74    155                                           .403                                                0.846 (0.573‐1.251)   89                                            139                                                 .942    1.014 (0.699‐1.470)                           59                                                  161   .241     1.277 (0.849‐1.920)
  rs8008130                                                                                                                                                                                                                                                                                                                                                                
  AA              128   281                                                                                               1                     161                                           245                                                         1                                             114                                                 279            1
  AG              22    54                                            .819                                                1.066 (0.615‐1.850)   29                                            47                                                  .856    0.953 (0.568‐1.600)                           23                                                  48    .506     0.827 (0.473‐1.447)
  GG              1     6                                             .329                                                2.919 (0.340‐9.021)   2                                             5                                                   .444    1.930 (0.359‐9.379)                           1                                                   6     .331     2.937 (0.335‐5.729)
  AG + GG         23    60                                            .614                                                1.148 (0.672‐1.960)   31                                            52                                                  .962    1.012 (0.614‐1.668)                           24                                                  54    .737     1.097 (0.638‐1.887)
  rs4144657                                                                                                                                                                                                                                                                                                                                                                
  CC              45    96                                                                                                1                     58                                            83                                                          1                                             43                                                  94             1
  CT              78    183                                           .903                                                1.029 (0.653‐1.621)   101                                           157                                                 .703    1.087 (0.707‐1.673)                           74                                                  174   .808     1.059 (0.666‐1.686)
  TT              28    62                                            .855                                                0.947 (0.530‐1.693)   33                                            57                                                  .653    1.136 (0.651‐1.982)                           21                                                  65    .309     1.381 (0.741‐2.573)
  CT + TT         106   245                                           .976                                                1.007 (0.653‐1.551)   134                                           214                                                 .650    1.100 (0.729‐1.659)                           95                                                  239   .585     1.132 (0.726‐1.764)
  rs2152278                                                                                                                                                                                                                                                                                                                                                                
  GG              63    114                                                                                               1                     71                                            105                                                         1                                             45                                                  127            1
  GT              69    174                                           .125                                                1.395 (0.912‐2.135)   97                                            144                                                 .822    1.048 (0.698‐1.574)                           75                                                  154   .105     0.689 (0.439‐1.081)
  TT              19    53                                            .176                                                1.532 (0.826‐2.841)   24                                            48                                                  .297    1.367 (0.760‐2.458)                           18                                                  52    .978     0.991 (0.519‐1.892)
  GT + TT         88    227                                           .085                                                1.425 (0.952‐2.133)   121                                           192                                                 .591    1.112 (0.755‐1.639)                           93                                                  206   .186     0.748 (0.486‐1.151)
  rs8012083                                                                                                                                                                                                                                                                                                                                                                
  AA              78    205                                                                                               1                     109                                           171                                                         1                                             76                                                  194            1
  AG              61    119                                           .243                                                0.783 (0.519‐1.181)   69                                            111                                                 .632    1.101 (0.743‐1.633)                           47                                                  127   .639     1.110 (0.717‐1.719)
  GG              12    17                                            .141                                                0.551 (0.249‐1.218)   14                                            15                                                  .261    0.639 (0.292‐1.396)                           15                                                  12    *.005*   *0.305 (0.135‐0.693)*
  AG + GG         73    136                                           .139                                                0.744 (0.503‐1.100)   83                                            126                                                 .925    1.018 (0.700‐1.481)                           62                                                  139   .640     0.907 (0.603‐1.364)
  rs7142488                                                                                                                                                                                                                                                                                                                                                                
  TT              120   280                                                                                                                     154                                           244                                                                                                       110                                                 272             
  TC              31    60                                            .626                                                0.884 (0.539‐1.451)   38                                            52                                                  .539    0.861 (0.535‐1.387)                           28                                                  60    .843     0.949 (0.568‐1.586)
  CC              0     1                                             1                                                   0                     0                                             1                                                   1       0                                             0                                                   1     1        0
  TC + CC         31    61                                            .672                                                0.899 (0.548‐1.410)   38                                            53                                                  .587    0.877 (0.545‐1.410)                           28                                                  61    .899     0.967 (0.580‐1.614)

*P* values adjusted for age, menarche age, menopausal status, number of pregnancies, number of abortions, history of breastfeeding, and family history of breast cancer in first‐degree relatives in logistic regression analysis.

The italic values represent*P* \< .05.
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3.5. Molecular typing of BC and the genotypes of nine SNPs {#cam42893-sec-0020}
----------------------------------------------------------

Table [5](#cam42893-tbl-0005){ref-type="table"} showed the association between nine SNPs of *LINC00520* and the different molecular typing states of BC. The genotypic GG (OR:3.58, 95%CI:1.32‐9.69) in rs8012083 increased the risk of triple‐negative BC.

###### 

Association analysis between three SNPs in *LINC00520* and molecular typing of breast cancer

  SNPs         Luminal   HER‐2   Triple‐negative                                                                                      
  ------------ --------- ------- ----------------- --------------------- ---- ----- ------- --------------------- ---- ----- -------- -----------------------
  rs11622641                                                                                                                          
  CC           302       113                       1.000                 71   344           1.000                 42   373            1.000
  CT           40        14      .973              0.989 (0.511‐1.915)   7    47    .532    0.764 (0.328‐1.777)   7    47    .384     1.486 (0.610‐3.623)
  TT           2         0       1.000             0                     0    2     1.000   0                     0    2     1.000    0
  CT + TT      42        14      .867              1.058 (0.549‐2.036)   7    49    .450    0.723 (0.312‐1.676)   7    49    .460     1.395 (0.576‐3380)
  rs7157819                                                                                                                           
  CC           260       97                        1.000                 60   297           1.000                 37   320            1.000
  CT           78        29      .765              0.927 (0.564‐1.525)   17   90    .953    0.982 (0.540‐1.786)   12   95    .653     1.178 (0.577‐2.407)
  TT           6         1       .564              1.878 (0.221‐5.991)   1    6     .924    0.901 (0.104‐7.775)   0    7     1.000    0
  CT + TT      84        30      .867              0.959 (0.588‐1.565)   18   96    .939    0.977 (0.544‐1.756)   12   102   .776     1.109 (0.544‐2.262)
  rs12880540                                                                                                                          
  TT           146       54                        1.000                 33   167           1.000                 21   179            1.000
  TG           151       55      .877              1.036 (0.662‐1.622)   33   173   .914    0.971 (0.570‐1.656)   22   184   .931     0.972 (0.507‐1.863)
  GG           47        18      .614              0.848 (0.447‐1.609)   12   53    .625    1.203 (0.574‐2.521)   6    59    .874     1.083 (0.407‐2.876)
  TG + GG      198       73      .955              0.988 (0.649‐1.503)   45   226   .926    1.024 (0.623‐1.684)   28   243   .986     0.994 (0.538‐1.838)
  rs2152275                                                                                                                           
  TT           186       65                        1.000                 42   209           1.000                 23   228            1.000
  TA           132       54      .471              0.853 (0.554‐1.314)   31   155   .958    0.986 (0.590‐1.649)   23   163   .257     1.439 (0.767‐2.699)
  AA           26        8       .850              1.086 (0.463‐2.549)   5    29    .773    0.861 (0.312‐2.376)   3    31    .890     1.095 (0.304‐3.948)
  TA + AA      158       62      .558              0.883 (0.583‐1.338)   36   184   .894    0.967 (0.591‐1.583)   26   194   .292     1.388 (0.755‐2.553)
  rs8008130                                                                                                                           
  AA           284       109                       1.000                 69   324           1.000                 40   353            1.000
  AG           54        17      .663              1.144 (0.625‐2.092)   9    62    .360    0.701 (0.328‐1.498)   8    63    .636     1.224 (0.530‐2.824)
  GG           6         1       .367              2.694 (0.312‐3.239)   0    7     .999    0                     1    6     .884     1.181 (0.126‐2.109)
  AG + GG      60        18      .490              1.229 (0.685‐2.204)   9    69    .220    0.625 (0.294‐1.326)   9    69    .626     1.219 (0.550‐2.701)
  rs4144657                                                                                                                           
  CC           96        41                        1.000                 22   115           1.000                 19   118            1.000
  CT           186       62      .389              1.234 (0.765‐1.989)   39   209   .934    0.976 (0.546‐1.743)   23   225   .251     0.675 (0.345‐1.321)
  TT           62        24      .973              1.011 (0.550‐1.858)   17   69    .420    1.340 (0.657‐2.731)   7    79    .289     0.603 (0.237‐1.535)
  CT + TT      248       86      .496              1.170 (0.745‐1.838)   56   278   .826    1.064 (0.614‐1.842)   30   304   .193     0.656 (0.348‐1.237)
  rs2152278                                                                                                                           
  GG           117       55                        1.000                 33   139           1.000                 22   150            1.000
  GT           173       56      .134              1.412 (0.900‐2.217)   33   196   .205    0.706 (0.412‐1.210)   23   206   .536     0.817 (0.429‐1.552)
  TT           51        16      .199              1.537 (0.798‐2.959)   12   58    .701    0.865 (0.413‐1.812)   4    66    .158     0.445 (0.145‐1.367)
  GT + TT      227       72      .094              1.440 (0.940‐2.206)   45   54    .247    0.742 (0.448‐1.229)   27   272   .308     0.725 (0.391‐1.344)
  rs8012083                                                                                                                           
  AA           203       67                        1.000                 43   227           1.000                 24   246            1.000
  AG           125       49      .626              0.896 (0.577‐1.391)   31   143   .678    1.115 (0.667‐1.863)   18   156   .817     1.082 (0.557‐2.100)
  GG           26        11      .080              0.476 (0.207‐1.094)   4    23    .950    0.965 (0.314‐2.962)   7    20    *.012*   *3.575 (1.318‐9.698)*
  AG + GG      141       60      .340              0.816 (0.538‐1.239)   35   166   .719    1.095 (0.667‐1.797)   25   176   .324     1.359 (0.739‐2.498)
  rs7142488                                                                                                                           
  TT           281       101                       1.000                 63   319           1.000                 38   344            1.000
  TC           62        26      .749              0.918 (0.542‐1.553)   15   73    .905    1.039 (0.552‐1.956)   11   77    .737     1.135 (0.542‐2.378)
  CC           1         0       1                 0                     0    1     1       0                     0    1     1        0
  TC + CC      63        26      .793              0.932 (0.551‐1.576)   15   74    .934    1.027 (0.546‐1.932)   11   78    .765     1.120 (0.535‐2.345)

*P* values adjusted for age, menarche age, menopausal status, number of pregnancies, number of abortions, history of breastfeeding, and family history of breast cancer in first‐degree relatives in logistic regression analysis.

The italic values represent*P* \< .05.

John Wiley & Sons, Ltd

3.6. Analysis of haplotype {#cam42893-sec-0021}
--------------------------

The haplotype analysis was conducted to evaluate the combined effect of four *LINC00520* SNPs. As shown in Table [6](#cam42893-tbl-0006){ref-type="table"}, C~rs7157819~T~rs12880540~A~rs2152275~T~rs11622641~ was the common haplotype in cases and controls with a frequency of 0.05% and 0.078%, respectively, and could decrease BC risk by 37% (OR:0.63, 95%CI:0.44‐0.91). However, other results showed that no haplotype was associated with BC risk with *P* \< .05.

###### 

Haplotype analysis of four SNPs in *LINC00520*

  Gene          Haplotype[a](#cam42893-note-0013){ref-type="fn"}   Cases (%)        Controls (%)     χ^2^     *P*                     OR (95%CI)
  ------------- -------------------------------------------------- ---------------- ---------------- -------- ----------------------- ---------------------
  *LINC00520*   C G A C                                            174.34 (0.173)   164.71 (0.163)   0.349    .554                    1.073 (0.849‐1.356)
  C G T C       53.43 (0.053)                                      47.25 (0.047)    0.409            .522     1.140 (0.763‐1.704)     
  C T A C       29.54 (0.029)                                      19.89 (0.020)    1.948            .163     1.502 (0.845‐2.671)     
  C T A T       50.10 (0.050)                                      77.68 (0.077)    6.316            *.012*   *0.627 (0.435‐0.905)*   
  C T T C       556.93 (0.553)                                     572.14 (0.566)   0.418            .518     0.943 (0.790‐1.126)     
  T G T C       128.34 (0.127)                                     112.65 (0.112)   1.193            .275     1.162 (0.887‐1.522)     

Abbreviation: SNPs, single‐nucleotide polymorphisms.

The sequence of SNP locus is rs7157819, rs12880540, rs2152275, and rs11622641.

The italic values represent*P* \< .05.

John Wiley & Sons, Ltd

3.7. Gene‐reproductive factor interaction analysis {#cam42893-sec-0022}
--------------------------------------------------

We further explored the interaction between functional SNPs and other factors on BC risk using multifactor dimensionality reduction (MDR) analysis (Table [7](#cam42893-tbl-0007){ref-type="table"}). The optimal gene‐environment interactive model with testing balance accuracy (TBA) of 0.70 and cross‐validation consistency (CVC) of 7/10 revealed that the number of pregnancies more than twice with number of abortions more than twice carrying rs2152278 T allele had 5.24 times higher risk of BC over those without above characteristics.

###### 

Interaction analyses between the functional SNPs and environmental factors associated with breast cancer by MDR

  Model                                                   TBA     CVC     χ^2^      *P*        OR (95%CI)
  ------------------------------------------------------- ------- ------- --------- ---------- -----------------------
  Number of pregnancies                                   0.596   10/10   31.413    *\<.001*   *2.049 (1.592‐2.637)*
  Number of pregnancies, number of abortions              0.688   10/10   143.543   *\<.001*   *4.935 (3.774‐6.454)*
  Number of pregnancies, number of abortions, rs2152278   0.696   10/10   154.784   *\<.001*   *5.239 (4.006‐6.853)*

The best model was selected as the one with the maximum testing balance accuracy and maximum cross‐validation consistency.

In this study, the best interaction model was the three‐factor model including number of pregnancies‐number of abortions‐*LINC00520* rs2152278.

Abbreviations: CVC, cross‐validation consistency; MDR, multifactor dimensionality reduction; SNPs, single‐nucleotide polymorphisms; TBA, testing balance accuracy.

John Wiley & Sons, Ltd

3.8. Functional correlation of rs12880540 genotypes with the relative expression of *LINC00520* in plasma {#cam42893-sec-0023}
---------------------------------------------------------------------------------------------------------

As shown by qRT‐PCR analyses (Figure [1](#cam42893-fig-0001){ref-type="fig"}), the average relative expression of *LINC00520* in the plasma of individuals with rs12880540 TG (1.61 ± 0.35, n = 44) and rs12880540 GG (2.25 ± 0.29, n = 22) was both higher (both *P* \< .0029) than those only with rs12880540 TT (1.03 ± 0.48, n = 40). Furthermore, with the increase of C genotype, *LINC00520* expression appeared to be elevated.

![The relative expression of *LINC00520* with different rs12880540 genotypes in plasma. The relative mRNA expression of *LINC00520* levels in blood plasma from 106 cancer‐free controls was significantly higher in the TG (1.61 ± 0.35) and GG genotypes (2.25 ± 0.29) than the TT genotype (1.03 ± 0.48) (all *P* \< .001)](CAM4-9-2252-g001){#cam42893-fig-0001}

3.9. Effect of rs12880540 mutation on the binding of miR‐3122 and ***LINC00520*** {#cam42893-sec-0024}
---------------------------------------------------------------------------------

As the database predicted, rs12880540 G \> T mutation could gain/loss a binding site for miR‐3122 and *LINC00520*, which might regulate the expression of *LINC00520* (Figure [2](#cam42893-fig-0002){ref-type="fig"}). To investigate the effect of rs12880540 on the binding of miR‐3122 and *LINC00520*, we constructed luciferase reporter containing part of *LINC00520* covering rs12880540 G \> T allele co‐transfected with miRNA mimics in 293T cells, measured and calculated the relatively luciferase activity. Luciferase reporter assays displayed that the luciferase activity of the construct with the risk rs12880540 G allele decreased when transfected with miR‐3122 mimics and there was no change when transfected with NC, which not indicated that rs12880540 G would affect the combination of miR‐3122 and *LINC00520*.

![The effect of rs12880540 on the binding of miR‐3122 and *LINC00520* revealed by luciferase reporter assays](CAM4-9-2252-g002){#cam42893-fig-0002}

4. DISCUSSION {#cam42893-sec-0025}
=============

So far as we know, no association between genetic variation of *LINC00520* and BC susceptibility has been explored. In the study, a case‐control research was conducted to analyze the association between *LINC00520* genetic susceptibility and the risk of BC. After adjusted by age, menarche age, menopausal status, number of pregnancies, number of miscarriages, history of breastfeeding, and family history of BC, the study found that the variation of rs11622641 allele was statistically associated with a reduced risk of BC. The variation of rs12880540 and rs2152278 alleles increased the risk of BC. The results showed that TG, rs2152275 genotype TG, and rs8012083 genotype AA of rs12880540 genotype GG were significantly correlated with the positive status of Her‐2 receptor. Haplotype analysis showed that *LINC00520* C~rs7157819~ T~rs12880540~ A~rs2152275~ T~rs11622641~ haplotype could reduce the risk of BC. The homozygous mutant GG at rs8012083 site could significantly increase the risk of triple‐negative BC. A genetic variant of rs8012083 in *LINC00520* could be used as a biomarker for triple‐negative BC. However, the mechanism of its influence on the susceptibility to triple‐negative BC needed to be further studied.

Previous studies have shown that SNP could affect the level of genes expression through allelic changes, thus participating in the carcinogenesis of tumor. Compared with rs619586 A allele, the expression of *MALAT1* in individuals carrying rs619586 G allele was lower, which might be related to the decreased susceptibility to BC.[20](#cam42893-bib-0020){ref-type="ref"} The G risk gene of rs6983267 site of lncRNA *CCAT2* could increase the expression of *CCAT2*, which was related to the risk of colorectal cancer.[21](#cam42893-bib-0021){ref-type="ref"} The results showed that the genotype GG at rs12880540 site significantly increased the risk of BC compared with the genotype TT. The relative expression of *LINC00520* showed a linear trend with the increase in the number of rs12880540 mutations. It was suggested that *LINC00520* gene polymorphism could increase the risk of BC and affect the expression of *LINC00520* in plasma, which played an important role in the occurrence and development of BC, consistent with the results of the increased expression of *LINC00520* in BC.[19](#cam42893-bib-0019){ref-type="ref"}

The SNP mutations could change the activity of lncRNAs transcriptional regulatory region and affect the expression of lncRNAs by changing the secondary structure of lncRNAs to obtain or lose the binding site of miRNAs, thus affecting the development, metastasis, and prognosis of tumor.[22](#cam42893-bib-0022){ref-type="ref"}, [23](#cam42893-bib-0023){ref-type="ref"}, [24](#cam42893-bib-0024){ref-type="ref"} The biological function of the secondary structure and the miRNA binding ability of the SNPs of the *LINC00520* were predicted using the lncRNASNP2 database (<http://bioinfo.life.hust.edu.cn/lncRNASNP>) and the RNAfold website (<http://rna.tbi.univie.ac.at/cgi-bin/RNAWebSuite/RNAfold.cgi>). The predicted results showed that the secondary structure of the *LINC00520* has changed after the mutation of the rs12880540 allele G to T, while the two binding sites of the miR‐92a‐2‐5p and the miR‐4648 and the four binding sites of the miR‐3122, the miR‐3913‐5p, the miR‐4259, and the miR‐4425 were lost. The results of double luciferase reporter gene experiment showed that *LINC00520* and miR‐3122 interact with each other because of T, but the variation of rs12880540 G \> T had little effect on the binding ability of *LINC00520* and miR‐3122. Therefore, the effect of rs12880540 G \> T on BC susceptibility may not be due to its change in binding ability of *LINC00520* to miR‐3122.

BC is a disease with extremely complex pathogenesis. It is generally believed that BC is the result of the interaction of many factors, such as personal lifestyle, environment, genetic, and reproductive factors.[25](#cam42893-bib-0025){ref-type="ref"} So far, studies have found individual or family history of smoking, drinking, obesity, menarche at earlier age, late menopausal, infertile, multiple miscarriages, genetic factors BC or ovarian cancer, genetic mutations, endogenous hormone exposure, and exogenous hormone intake (oral contraceptive and hormone replacement therapy), as well as other environmental and reproductive factors as risk factors for BC, while breastfeeding and physical activity were well‐known protective factors.[26](#cam42893-bib-0026){ref-type="ref"}, [27](#cam42893-bib-0027){ref-type="ref"}, [28](#cam42893-bib-0028){ref-type="ref"}, [29](#cam42893-bib-0029){ref-type="ref"} The results of this study showed that there was obvious interaction between the number of pregnancies, the number of miscarriages, and rs2152278. However, the mechanism of its interaction needs to be further studied.

For the first time, we found the association between *LINC00520* gene polymorphism and BC susceptibility. The following were advantages of this study. First of all, all the cases included in this study were new cases of BC with definite pathological diagnosis, which was beneficial to the control of current cases‐new cases bias. Secondly, the health control randomly selected from the community chronic disease survey of 20 000 people in Henan Province was used in this study. The age matching (±2 years old) between the case and the control made basic characteristics of the two groups similar, which was helpful to reduce confusion bias. Finally, 5% of the DNA samples were randomly selected for repeated experiments, and the different genotypes of each SNP were randomly selected for sequencing, so as to verify the consistency of the experimental results.

Inevitably, the study also has some limitations. The number of samples was 1009 and this study only aimed at the Chinese Han population, leading to the limited representativeness and universality of this study. Therefore, a larger sample size is needed to verify the experimental results of this study. Secondly, this study only aimed at the Chinese Han population. Due to ethnic or regional differences, the results of this study need to be verified by other regions and ethnic groups. Finally, because of the lack of relevant research of the *LINC00520* and adequate reference and related biological function theory support, the research on the function of the *LINC00520* gene only has a preliminary foundation study, which needs further research.

In conclusion, a genetic variant of rs8012083 in *LINC00520* could be used as a biomarker for triple‐negative BC after further evaluation of diagnostic tests. The genetic variant of *LINC00520* was related to the susceptibility of BC, and rs12880540 might affect the corresponding mRNA expression of lncRNA *LINC00520*.
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